NewsIn memory
Betty Ford's Breast Cancer and the Conversation She Started
First Lady Betty Ford spoke openly about her 1974 breast cancer, helping millions of women feel able to talk about it. Here's what breast cancer is.
A plain-language summary based on public reporting and trusted sources, linked below.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
The First Lady who refused the silence
The National Archives records the dates. Betty Ford was diagnosed with breast cancer on September 26, 1974, weeks after becoming First Lady. She had a mastectomy two days later.
She then did something almost no one did in 1974. She said so, publicly, and explained why.
"There had been so much cover-up during Watergate that we wanted to be sure there would be no cover-up in the Ford administration," she recalled. "So rather than continue this traditional silence about breast cancer, we felt we had to be very public."
The effect was measurable. The Archives notes that "record numbers of women received breast examinations, many for the first time," an episode still called the "Betty Ford blip." She was, the Archives notes, one of about 90,000 American women diagnosed with breast cancer that year.
A year later she added a line worth keeping. "Cancer wherever it strikes the body, also strikes the spirit," she said in November 1975, "and the best doctors in the world can't cure the spirit, only love and understanding can."
Her care in 1974 was her own, and it is not described further here. What has changed since is worth knowing.
What the disease is
Breast cancer starts when cells in the breast grow without control. The National Cancer Institute (NCI) calls it the most common noncutaneous cancer in US women. About 321,910 new cases of invasive disease and 42,140 deaths are what the American Cancer Society projects for 2026; the 316,950 and 42,170 that NCI's summary passes along are the 2025 pair.
Most cases begin in one of two places. Ductal carcinoma, starting in the milk ducts, makes up 70% to 80%. Lobular carcinoma, starting in the milk-producing lobules, makes up 10% to 15%.
Lobular cancer has a quirk worth knowing. It lacks a protein called E-cadherin, so it grows in single-file lines rather than a lump. NCI notes this lowers the sensitivity of mammography and raises the value of MRI.
There is also ductal carcinoma in situ, or DCIS, which the American Cancer Society put at about 59,080 cases in its 2025 projection. "In situ" means abnormal cells are still confined inside the duct.
Three tests that decide almost everything
Every invasive breast cancer is tested for three markers, and the answers steer treatment more than tumor size does.
ER stands for estrogen receptor. PR stands for progesterone receptor. A tumor counts as positive when at least 1% of cells stain for them. Positive tumors can often be treated with hormone-blocking drugs.
HER2 is a growth-signaling protein. HER2-positive tumors respond to drugs built specifically against it.
A tumor negative for all three is called triple-negative. It does not respond to hormone or HER2 drugs, so chemotherapy carries more of the load.
The surgery question was settled by a trial
For decades, more surgery was assumed to mean better survival. A trial disproved it.
NCI describes the NSABP B-06 trial as foundational. It established that breast-conserving surgery plus radiation gives survival equivalent to mastectomy in early-stage disease. That single finding reshaped how breast cancer is treated worldwide.
The armpit changed too. Removing all the lymph nodes under the arm causes lasting arm swelling, called lymphedema. NCI notes that sentinel lymph node biopsy has replaced routine axillary dissection when nodes appear clear on examination. It samples only the first node or two the tumor drains into, which keeps staging accurate and cuts the harm.
Tests that subtract treatment
The newer shift is about giving less chemotherapy, not more.
For hormone receptor-positive, node-negative disease, the Oncotype DX 21-gene recurrence score sorts patients. NCI reports that a score of 11 or under means chemotherapy is not indicated. A score above 25 means it is. Scores in between were the hard cases.
The TAILORx trial answered that middle band. Among postmenopausal women scoring 11 to 25, nine-year outcomes were 83.3% with hormone therapy alone and 84.3% with hormone therapy plus chemotherapy. That met the bar for non-inferiority, meaning many women could skip chemotherapy safely.
RxPONDER extended it. In postmenopausal patients with scores of 25 or less, adding chemotherapy gave a hazard ratio of 0.97, meaning no benefit. Premenopausal patients did benefit, with a hazard ratio of 0.54.
The MammaPrint 70-gene signature works similarly. In the MINDACT trial, women at high clinical risk but low genomic risk who skipped chemotherapy had 94.7% five-year survival without distant spread.
Changes worth an appointment
Ask to be seen for any of these:
- A new lump or firm thickening in the breast or armpit that is still there after one menstrual cycle
- Skin that dimples, puckers, or takes on an orange-peel texture
- A nipple that has newly turned inward
- Spontaneous discharge from one nipple, especially if bloody or clear
- A scaly, itchy rash on the nipple that has not healed in two weeks
- Any of the above in a man, which happens and is often diagnosed late
Seek care within days for a breast that becomes red, hot, swollen, and heavy over a few weeks. That can be an infection, and it can also be inflammatory breast cancer, which does not form a lump.
Where the numbers stand now
SEER, the federal cancer surveillance program, puts five-year relative survival for female breast cancer at 91.9%, measured on diagnoses from 2016 through 2022. For 2026 it lists about 321,910 new cases and about 42,140 deaths, figures the American Cancer Society projects. Incidence is 132.5 per 100,000 women per year, and the death rate is 18.9 per 100,000.
That survival figure is a national average built from hundreds of thousands of people with very different tumors. It reflects real progress since 1974. It does not describe any individual.
Sources
- https://www.cancer.gov/types/breast/hp/breast-treatment-pdq
- https://seer.cancer.gov/statfacts/html/breast.html
- https://visit.archives.gov/whats-on/explore-exhibits/betty-ford-raising-breast-cancer-awareness
- https://ford.blogs.archives.gov/2024/09/26/betty-ford-breast-cancer/
- https://www.cancer.org/research/cancer-facts-statistics.html
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Breast cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.